Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Eisai amends Aduhelm collaboration with Biogen

By Brian Buntz | March 15, 2022

Biogen/EisaiAduhelm (aducanuamab) co-developer Eisai Co. (TYO:4523) has agreed to modify its economic partnership agreement with Biogen (Nasdaq:BIIB).

Starting January 1, 2023, Eisai will receive a tiered royalty on net sales of the Alzheimer’s disease therapy Aduhelm (aducanumab) rather than share profits or losses of the drug.

Eisai would receive between 2% and 8% of annual sales of the Aduhelm.

The Tokyo-based company also has given Biogen total decision-making power and commercialization rates globally for Aduhelm.

Analysts’ projections for Aduhelm have dimmed significantly in the wake of the drug’s approval by FDA in June 2021.

Eisai’s partnership with Biogen on the investigational Alzheimer’s drug lecanemab collaboration will remain unchanged globally. The two companies, however, have agreed to extend a supply agreement from five to 10 years that would have Biogen manufacture the drug candidate.

Lecanemab, like aducanumab, is also an amyloid beta-protein inhibitor.

The two companies had previously agreed to share international profits and losses of the Alzheimer’s drug Aduhelm, which was FDA approved last year but has found limited use to date.

CMS plans on announcing its final national coverage determination for drugs in the same class as Aduhelm in April. In addition, the agency announced draft guidance in January, recommending the drug only for clinical trial participants.

In 2022, Eisai will cover up to $335 million in Aduhelm development, manufacturing, and commercialization costs.

“We believe this new arrangement will be more effective and enable more focused execution with the goal of maximizing the value of both ADUHELM and lecanemab,” said Haruo Naito, CEO at Eisai, in a statement. “Eisai will increase its focus on lecanemab and remains committed to bringing a new treatment option expeditiously to patients in need worldwide.”


Filed Under: Neurological Disease
Tagged With: Aducanumab, Aduhelm, Biogen, Eisai, lecanemab
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Aduhelm
Nine out of ten U.S. neurologists have Aduhelm efficacy doubts
Athira Pharma
​​Athira Pharma to continue open-label Alzheimer’s extension studies
Biogen
Biogen CEO Michel Vounatsos to step aside as Aduhelm sales continue to sputter
Janssen
Why Janssen’s nipocalimab could represent a ‘pipeline in a pathway’

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50